UTC Aerospace Systems

Morphogenesis is a Phase 3 registration-stage immuno-oncology company based in Oldsmar, FL, dedicated to developing novel technologies to overcome resistance to cancer immunotherapy. Their leading IFx technology focuses on personalized cancer vaccines to combat tumor resistance to immunotherapies like checkpoint inhibitors, with plans to initiate a Phase 3 trial for aggressive skin cancer in 2024. Additionally, they are utilizing their Delta technology to develop bi-functional antibody drug conjugates (ADCs) that target Myeloid Derived Suppressor Cells (MDSCs) and modulate their immunosuppressive effects on the tumor microenvironment, aiming to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in cancer treatment. Morphogenesis is advancing two proprietary technologies to address the major obstacles limiting the effectiveness of cancer immunotherapies. Their IFx technology harnesses the power of the innate immune response by tricking the body's immune system to recognize tumor cells as bacteria, while their bi-functional ADCs, developed using Delta receptor technology, target MDSCs to inhibit their immune suppressing effects and prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. With a focus on overcoming primary and acquired resistance, Morphogenesis is committed to developing innovative solutions to enhance the efficacy of cancer immunotherapies.Generated from the website